For the first time in Asia, the personalized tumor vaccine encoding neoantigen mRNA from Sri Lanka entered the overseas clinical stage

Recently, the personalized tumor vaccine encoding neoantigen mRNA developed by Sri Lanka has obtained formal ethics approval in Australia, and has officially entered the phase I clinical phase of overseas registration
.

It is reported that this is the first time in China and Asia
.

In a phase I clinical trial in Australia, Sterling will further explore the safety and efficacy of mRNA-encoded neoantigen-encoding mRNA personalized tumor vaccine therapy in patients with advanced malignant solid tumors
.

The first patient will be enrolled in March 2022
.

Patients with advanced malignant solid tumors, especially those with metastases, currently lack effective treatment methods, and the survival time is very short
.

mRNA tumor vaccine is known as the representative of the new generation of tumor precision immunotherapy, and has subversive advantages in immunogenicity, efficacy, safety and industrial production
.

With the help of next-generation sequencing technology, researchers can better understand the genetic mutation of patients; with the help of database and computer analysis, they can predict personalized neoantigens
.

Combined with mRNA coding technology, a personalized neoantigen tumor vaccine was born, which will provide new hope for the treatment of patients with advanced malignant solid tumors
.

The core technology of neoantigen mRNA personalized tumor vaccine is a new nanomaterial (Lipopolyplex, LPP) mRNA delivery system, which has a unique double-layer structure and can gradually release mRNA molecules with the degradation of the polymer, which can ensure the safety and safety of mRNA delivery.
effectiveness
.

The excellent dendritic cell targeting of the LPP platform can better activate the immune response of T cells through antigen presentation, thereby achieving an ideal immunotherapy effect
.

In animal tumor-bearing experiments, it was found that subcutaneous injection of LPP mRNA vaccine for three courses can significantly inhibit lung metastasis of melanoma; mRNA vaccine against breast cancer also showed better tumor inhibition effect
.

According to the clinical phase I trial data, the R&D team will more accurately locate the indications and patient populations of personalized tumor vaccines, and strive to seek the most effective treatment options to bring good news to patients
.

Sri Lanka microbiology R&D pipeline The Sri Lanka microbiology research and development pipeline is divided into two major directions: infectious diseases and immuno-oncology
.

Infectious diseases: Compared with traditional vaccines, mRNA vaccine technology has huge advantages in terms of efficacy, development speed, scalability and safety of production
.

Multiple viral antigens can be integrated into a single mRNA, which enables the production of complex multi-antigen vaccines that are difficult to achieve with traditional techniques
.

And the mRNA vaccine mimics the process of natural virus infection, which is beneficial to enhance the immune response of B cells and T cells
.

Tumor immunology: Malignant tumors have become the second leading cause of death after cardiovascular and cerebrovascular diseases
.

Immuno-oncology uses the body's immune system to identify and kill tumor cells to achieve the purpose of treating tumors
.

Siwei is committed to applying unique mRNA technology to the field of tumor immunotherapy, activating specific antigen T cells, improving the tumor immune microenvironment, and bringing revolutionary technology to tumor immunology research
.

In addition, Sterling Microbes is also studying the treatment of cardiovascular diseases through mRNA-induced stem cells
.

By transfecting fibroblasts with mRNA encoding reprogramming factors (Oct4, Sox2, c-Myc, Klf4), iPS cells are generated and induced to differentiate into cardiomyocytes to treat cardiovascular diseases
.

Reference link: https:// "Bioworld" recently launched the "mRNA" column, which interprets and introduces the latest research progress and reviews in the field of mRNA every week, as well as related startup company reports, interviews,
etc.

We have also established an mRNA exchange group, long press the QR code below, add the editor-in-chief WeChat, and note the unit-research direction/position-name
.

Open reprint welcome to forward to Moments and WeChat groups